Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
Restricted accessResearch articleFirst published online October, 2021
Mortality Rates After Paclitaxel-Coated Device Use in Patients With Occlusive Femoropopliteal Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
A late increased mortality risk has been reported in a summary level meta-analysis of patients with femoropopliteal artery occlusive disease treated with paclitaxel-coated angioplasty balloons and stents. However, at the longer follow up timepoints that analysis was limited by small trial numbers and few participants. The aim of this study was to report an updated summary level risk of all-cause mortality after treatment with paclitaxel-coated devices in that same patient group.
Materials and Methods:
We performed a systematic review and meta-analysis of randomized controlled trials to investigate the mortality outcomes associated with paclitaxel-coated devices used to treat patients with occlusive disease of femoropopliteal arteries (last search date December 10, 2020). The single primary endpoint was all-cause mortality.
Results:
We identified 34 randomized controlled trials (7654 patients; 84% intermittent claudication). There were 622 deaths among 4147 (15.0%) subjects in the paclitaxel device group and 475 deaths among 3507 (13.5%) subjects in the noncoated control group [relative risk ratio (RR) 1.07, 95% confidence interval (CI) 0.96 to 1.20, p=0.20, I2=0%). All-cause mortality was similar between groups at 12 months (34 studies, 7654 patients; RR 0.99, 95% CI 0.81 to 1.22, p=0.94, I2=0%), 24 months (20 studies, 3799 patients; RR 1.16, 95% CI 0.87 to 1.55, p=0.31, I2=0%), and 60 months (9 studies, 2288 patients; RR 1.19, 95% CI 0.98 to 1.45, p=0.08, I2=0%).
Conclusion:
This updated meta-analysis with included additional trials and larger patient numbers shows no evidence of increased risk of all-cause mortality in patients treated with paclitaxel-coated devices, compared with uncoated devices for femoropopliteal disease at all time points to 60 months. There is therefore no justification to limit their use, or alter regulatory body follow-up recommendations in this patient population.
CriquiMHAboyansV.Epidemiology of peripheral artery disease. Circ Res. 2015;116:1509–1526.
2.
TeraaMConteMSMollFL, et al. Critical limb ischemia: current trends and future directions. J Am Heart Assoc. 2016;5:e002938.
3.
JaffMRWhiteCJHiattWR, et al. An update on methods for revascularization and expansion of the TASC Lesion Classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther. 2015;22:663–677.
4.
Anantha-NarayananMShahSMJelaniQU, et al. Drug-coated balloon versus plain old balloon angioplasty in femoropopliteal disease: an updated meta-analysis of randomized controlled trials. Catheter Cardiovasc Interv. 2019;94:139–148.
5.
SalisburyACLiHVilainKR, et al. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9:2343–2352.
6.
KlumbCLehmannTAschenbachR, et al. Benefit and risk from paclitaxel-coated balloon angioplasty for the treatment of femoropopliteal artery disease: a systematic review and meta-analysis of randomised controlled trials. EClinicalMedicine. 2019;16:42–50.
7.
KatsanosKSpiliopoulosSKitrouP, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7:e011245.
8.
DinhKGomesMLThomasSD, et al. Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischemia: a systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther. 2020;27:175–185.
9.
DinhKLimmerAMParavastuSC, et al. Mortality after paclitaxel-coated device use in dialysis access: a systematic review and meta-analysis. J Endovasc Ther. 2019;26:600–612.
10.
FreisingerEKoeppeJGerssJ, et al. Mortality after use of paclitaxel-based devices in peripheral arteries: a real-world safety analysis. Eur Heart J. 2020;41:3732–3739.
11.
SecemskyEAKundiHWeinbergI, et al. Drug-eluting stent implantation and long-term survival following peripheral artery revascularization. J Am Coll Cardiol. 2019;73:2636–2638.
12.
DonasKPSohrAPitouliasGA, et al. Long-term mortality of matched patients with intermittent claudication treated by high-dose paclitaxel-coated balloon versus plain balloon angioplasty: a real-world study. Cardiovasc Intervent Radiol. 2020;43:2–7.
13.
WeisslerEHAnnapureddyAWangY, et al. Paclitaxel-coated devices in the treatment of femoropopliteal stenosis among patients ≥65 years old: an ACC PVI Registry analysis. Am Heart J. 2021;233:59–67.
14.
BehrendtCASedrakyanAPetersF, et al. Editor’s choice—long term survival after femoropopliteal artery revascularisation with paclitaxel coated devices: a propensity score matched cohort analysis. Eur J Vasc Endovasc Surg. 2020;59:587–596.
15.
ShishehborMHSecemskyEAVarcoeRL.Is there a real association between paclitaxel devices and mortality? Time to pause and re-evaluate what we know about this statistical finding. J Am Heart Assoc. 2019;8:e012524.
16.
SchneiderPAVarcoeRLSecemskyE, et al. Update on paclitaxel for femoral-popliteal occlusive disease in the 15 months following a summary level meta-analysis demonstrated increased risk of late mortality and dose response to paclitaxel. J Vasc Surg. 2021;73:311–322.
17.
MoherDShamseerLClarkeM, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.
18.
LairdJASchneiderPAJaffMR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12:e007702.
19.
SchneiderPABrodmannMMauriL, et al. Paclitaxel exposure: long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials. Catheter Cardiovasc Interv. 2020;96:1087–1099.
20.
SogaYIidaOUrasawaK, et al. Three-year results of the IN.PACT SFA Japan Trial comparing drug-coated balloons with percutaneous transluminal angioplasty. J Endovasc Ther. 2020;27:946–955.
21.
OurielK.In Depth Independent Safety Analysis by Syntactx (CRO) of the Lutonix SFA DCB. Paper presented at: Leipzig Interventional Course (LINC); 2020; Leipzig, Germany.
22.
DakeMDAnselGMBosiersM, et al. Paclitaxel-coated zilver PTX drug-eluting stent treatment does not result in increased long-term all-cause mortality compared to uncoated devices. Cardiovasc Intervent Radiol. 2020;43:8–19.
23.
DakeMD.No increased long-term all-cause mortality for the paclitaxel-coated Zilver PTX Drug-Eluting Stent compared to uncoated devices. Paper presented at: Vascular Interventional Advances (VIVA); November 8, 2019; Las Vegas, NV.
24.
HigginsJPAltmanDGGotzschePC, et al; on behalf of the Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
25.
DerSimonianRLairdN.Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
26.
XuYJiaXZhangJ, et al. Drug-coated balloon angioplasty compared with uncoated balloons in the treatment of 200 Chinese patients with severe femoropopliteal lesions: 24-month results of AcoArt I. JACC Cardiovasc Interv. 2018;11:2347–2353.
27.
AllamA.Drug eluting balloon angioplasty versus bare-metal stent in treating chronic total occlusion of femoro-popliteal arterial segment; a review of one-year outcome of 90 patients with TASC C and D Lesion. Eur J Vasc Endovasc Surg. 2019;58(suppl 3):E754–E755.
28.
GouefficYSauguetADesgrangesP, et al. A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE Trial. JACC Cardiovasc Interv. 2020;13:447–457.
29.
ScheinertDSchulteKLZellerT, et al. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.
30.
TepeGSchroederHAlbrechtT, et al. Paclitaxel-coated balloon vs uncoated balloon angioplasty for treatment of in-stent restenosis in the superficial femoral and popliteal arteries: the COPA CABANA Trial. J Endovasc Ther. 2020;27:276–286.
31.
AlbrechtTWaliszewskiMRocaC, et al. Two-year clinical outcomes of the CONSEQUENT Trial: can femoropopliteal lesions be treated with sustainable clinical results that are economically sound?Cardiovasc Intervent Radiol. 2018;41:1008–1014.
32.
BjörkmanPWeseliusEMVenermoM.No difference in mid-term and long-term mortality after vascular paclitaxel exposure. Ann Vasc Surg. 2021;72:253–260.
33.
BosiersMSetacciCDe DonatoG, et al. ZILVERPASS study: ZILVER PTX stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther. 2020;27:287–295.
34.
BrodmannMWernerMMeyerDR, et al; om behalf of the ILLUMENATE EU RCT Investigators IER. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European Randomized Clinical Trial 2-year results. JACC Cardiovasc Interv. 2018;11:2357–2364.
35.
DakeMDAnselGMJaffMR, et al; on behalf of the Zilver PTXI Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX Randomized Trial. Circulation. 2016;133:1472–1483.
36.
de BoerSWde VriesJWersonDA, et al; RAPID Trial Investigators. Drug coated balloon supported Supera stent versus Supera stent in intermediate and long-segment lesions of the superficial femoral artery: 2-year results of the RAPID Trial. J Cardiovasc Surg (Torino). 2019;60:679–685.
37.
FanelliFCannavaleACoronaM, et al. The “DEBELLUM”—lower limb multilevel treatment with drug eluting balloon—randomized trial: 1-year results. J Cardiovasc Surg (Torino). 2014;55:207–216.
38.
IidaOSogaYUrasawaK, et al; on behalf of the MDT-2113 SFA Japan Investigators. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019;93:664–672.
39.
KinstnerCMLammerJWillfort-EhringerA, et al. Paclitaxel-eluting balloon versus standard balloon angioplasty in in-stent restenosis of the superficial femoral and proximal popliteal artery: 1-year results of the PACUBA Trial. JACC Cardiovasc Interv. 2016;9:1386–1392.
40.
KrankenbergHTublerTIngwersenM, et al. Drug-coated balloon versus standard balloon for superficial femoral artery in-stent restenosis: the randomized Femoral Artery In-Stent Restenosis (FAIR) Trial. Circulation. 2015;132:2230–2236.
41.
KrishnanPFariesPNiaziK, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE Pivotal and Pharmacokinetic Studies. Circulation. 2017;136:1102–1113.
42.
MiuraTMiyashitaYSogaY, et al; on behalf of the DEBATE in SFA Investigators. Drug-eluting versus bare-metal stent implantation with or without cilostazol in the treatment of the superficial femoral artery. Circ Cardiovasc Interv. 2018;11:e006564.
43.
NordanstigJJamesSAnderssonM, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med. 2020;383:2538–2546.
44.
OttICasseseSGrohaP, et al. Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for Femoral Artery Disease (ISAR-STATH). Circulation. 2017;135:2218–2226.
45.
OttICasseseSGrohaP, et al. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): a randomized trial. J Am Heart Assoc. 2017;6:e006321.
RosenfieldKJaffMRWhiteCJ, et al; on behalf of the LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
48.
ScheinertDDudaSZellerT, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.
49.
SteinerSWillfort-EhringerASievertH, et al; on behalf of the RANGER SFA Investigators. 12-Month results from the first-in-human randomized study of the ranger paclitaxel-coated balloon for femoropopliteal treatment. JACC Cardiovasc Interv. 2018;11:934–941.
50.
TackeJMuller-HulsbeckSSchroderH, et al. The Randomized Freeway Stent Study: drug-eluting balloons outperform standard balloon angioplasty for postdilatation of nitinol stents in the sfa and pi segment. Cardiovasc Intervent Radiol. 2019;42:1513–1521.
51.
TeichgraberULehmannTAschenbachR, et al. Drug-coated balloon angioplasty of femoropopliteal lesions maintained superior efficacy over conventional balloon: 2-year results of the Randomized EffPac Trial. Radiology. 2020;295:478–487.
52.
TepeGSchnorrBAlbrechtT, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1pt A):102–108.
53.
WerkMAlbrechtTMeyerDR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.
54.
WerkMLangnerSReinkensmeierB, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.
55.
BjorkmanPKokkonenTAlbackA, et al. Drug-coated versus plain balloon angioplasty in Bypass Vein Grafts (the DRECOREST I-Study). Ann Vasc Surg. 2019;55:36–44.
56.
FalkowskiABogackiHSzemitkoM.Assessment of mortality and factors affecting outcome of use of paclitaxel-coated stents and bare metal stents in femoropopliteal PAD. J Clin Med. 2020;9:2221.
57.
LiaoCJSongSHLiT, et al. Randomized controlled trial of orchid drug-coated balloon versus standard percutaneous transluminal angioplasty for treatment of femoropopliteal artery in-stent restenosis. Int Angiol. 2019;38:365–371.
58.
LiistroFGrottiSPortoI, et al. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv. 2013;6:1295–1302.
59.
JiaXGuoW.New Long-term information on PTX Coated DCB 5-year results from the AcoArt I Study. Paper presented at: Leipzig Interventional Course (LINC); January 28–31, 2020; Leipzig, Germany.
60.
BrodmannM.Final long-term mortality results of paclitaxel-coated DCBs from the ILLUMENATE RCTs. Paper presented at: Leipzig Interventional Course (LINC); 2021; Leipzig, Germany.
61.
TzafririARParikhSAEdelmanER.Taking paclitaxel coated balloons to a higher level: Predicting coating dissolution kinetics, tissue retention and dosing dynamics. J Control Release. 2019;310:94–102.
62.
JiaXWeiG.New long-term information on PTX coated DCB 5-year results from the AcoArt I Study. Paper presented at: Leipzig Interventional Course (LINC); 2020; Leipzig, Germany.
63.
VardiMNovackVPencinaMJ, et al. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014;83:975–983.
64.
GrayWAKeirseKSogaY, et al; on behalf of the Imperial Investigators. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018;392:1541–1551.
65.
HendersonICBerryDADemetriGD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983.
66.
MamounasEPBryantJLemberskyB, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–3696.
67.
ShulmanLNBerryDACirrincioneCT, et al. Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014;32:2311–2317.
68.
SongJIDumaisMR.From yew to us: the curious development of taxol. JAMA. 1991;266:1281.
69.
WeaverBA.How taxol/paclitaxel kills cancer cells. Mol Biol Cell. 2014;25:2677–2681.
70.
MarupudiNIHanJELiKW, et al. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6:609–621.
71.
HillAB.The environment and disease: association or causation? 1965. J R Soc Med. 2015;108:32–37.
72.
Center for Devices and Radiological Health, US Food and Drug Administration. FDA Executive Summary: circulatory system devices panel meeting: general issues panel: paclitaxel-coated drug coated balloon and drug-eluting stent late mortality panel. Published 2019. Accessed May 24, 2021. https://www.fda.gov/media/127698/download
73.
HoldenAVarcoeRLJaffMR, et al. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26:467–470.
74.
Rocha-SinghKJDuvalSJaffMR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. Circulation. 2020;141:1859–1869.
75.
FarbAMaloneMMaiselWH.Drug-coated devices for peripheral arterial disease. N Eng J Med. 2021;384:99.
76.
SchroederHWernerMMeyerDR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European Randomized Clinical Trial (Randomized Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon). Circulation. 2017;135:2227–2236.
77.
GrayWAJaffMRParikhSA, et al. Mortality assessment of paclitaxel-coated balloons: patient-level meta-analysis of the ILLUMENATE clinical program at 3 years. Circulation. 2019;140:1145–1155.
